Dr. Parikh’s clinical area of focus is the utilization of minimally invasive techniques to treat patients with benign and malignant tumors within the Gastrointestinal (GI) and Genitourinary (GU) system. Dr. Parikh primarily treats patients with benign prostatic hyperplasia (BPH), prostate cancer and kidney cancer as well as primary and secondary liver cancer. As a widely recognized expert on the utilization of prostate artery embolization (PAE) for the management of patients with prostate cancer, Dr. Parikh is dedicated to advancing innovative oncologic care and founded the PAE program at Moffitt Cancer Center to help men who suffer from decreased urinary function. He has also published several manuscripts on the topic and currently serves as the primary investigator for a clinical trial studying the role of neoadjuvant PAE prior to definitive radiotherapy for men with prostate cancer (https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-2083…).Dr. Parikh also presently serves as the Assistant Chief Medical Officer. In this role, he uses his prior business experience to serve the institution with a focus on finance, strategy, digital innovation and clinical partnerships.Dr. Parikh earned his undergraduate degree from Columbia University and after working as an investment banker on Wall Street, he obtained MD and MBA degrees from Tufts University School of Medicine in Boston, MA. He then completed diagnostic radiology residency at NYU Medical Center in New York City, before moving back to Boston to complete a fellowship in Angiography and Interventional Radiology at the Brigham and Women’s Hospital – Harvard Medical School.